The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.

The invention provides branched trialkylamine oxides with improved properties. The trialkylamine oxides of the invention produced from branched trialkylamines, in one embodiment, can be made using certain branched C10-12 enals and aldehydes. The invention also provides an trialkylamine oxide having the formula: ##STR00001##
wherein R5, R6 and R7 are independently at least one of C3H7, C2H5, CH3, or H, or mixtures thereof; and wherein R5 and R6 are not H at the same time. In one embodiment, the trialkylamine oxides of the invention can be useful in making various products, for example, as surfactants.

The invention provides branched trialkylamine oxides with improved properties. The trialkylamine oxides of the invention produced from branched trialkylamines, in one embodiment, can be made using certain branched C10-12 enals and aldehydes. The invention also provides an trialkylamine oxide having the formula: ##STR00001##
wherein R5, R6 and R7 are independently at least one of C3H7, C2H5, CH3, or H, or mixtures thereof; and wherein R5 and R6 are not H at the same time. In one embodiment, the trialkylamine oxides of the invention can be useful in making various products, for example, as surfactants.

A method of producing pharmaceutical grade bretylium tosylate comprising low amounts of mutagenic impurities. The method comprises forming bretylium tosylate having a purity of less than 99.5% and purifying the bretylium tosylate by: i) forming a slurry of the bretylium tosylate with a mixture of acetone and ethyl acetate; ii) filtering the slurry to obtain purified bretylium tosylate. The bretylium tosylate so produced has a purity of at least 99.5%, and suitably comprises less than 0.5 ppm of the potentially mutagenic impurity ethyl p-toluenesulfonate. The bretylium tosylate so produced also suitably comprises less than 0.5 ppm of the potentially mutagenic impurity 2-bromobenzylbromide.

A method of producing pharmaceutical grade bretylium tosylate comprising low amounts of mutagenic impurities. The method comprises forming bretylium tosylate having a purity of less than 99.5% and purifying the bretylium tosylate by: i) forming a slurry of the bretylium tosylate with a mixture of acetone and ethyl acetate; ii) filtering the slurry to obtain purified bretylium tosylate. The bretylium tosylate so produced has a purity of at least 99.5%, and suitably comprises less than 0.5 ppm of the potentially mutagenic impurity ethyl p-toluenesulfonate. The bretylium tosylate so produced also suitably comprises less than 0.5 ppm of the potentially mutagenic impurity 2-bromobenzylbromide.

A method of producing pharmaceutical grade bretylium tosylate comprising low amounts of mutagenic impurities. The method comprises forming bretylium tosylate having a purity of less than 99.5% and purifying the bretylium tosylate by: i) forming a slurry of the bretylium tosylate with a mixture of acetone and ethyl acetate; ii) filtering the slurry to obtain purified bretylium tosylate. The bretylium tosylate so produced has a purity of at least 99.5%, and suitably comprises less than 0.5 ppm of the potentially mutagenic impurity ethyl p-toluenesulfonate. The bretylium tosylate so produced also suitably comprises less than 0.5 ppm of the potentially mutagenic impurity 2-bromobenzylbromide.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.

Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as biaryl compound), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.

The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of formula: ##STR00001##

The surfactants which can be produced from the trialkylamine intermediates include the quaternary ammonium compounds of formula: ##STR00001##